{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:14:24Z","timestamp":1769073264012,"version":"3.49.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.juro.2017.10.041","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T22:00:18Z","timestamp":1509832818000},"page":"1129-1142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma"],"prefix":"10.1097","volume":"199","author":[{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"first","affiliation":[{"name":"The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"Moffit Cancer Center, Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.10.041_bib1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1586\/era.09.146","article-title":"Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure","volume":"9","author":"Siefker-Radtke","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.juro.2017.10.041_bib2","series-title":"Prescribing Information","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib3","series-title":"Prescribing Information","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib4","series-title":"Prescribing Information","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib5","series-title":"Prescribing Information","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib6","series-title":"Prescribing Information","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2004.08.002","article-title":"Focus on bladder cancer","volume":"6","author":"Dinney","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.juro.2017.10.041_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.juro.2017.10.041_bib9","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2017.10.041_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.juro.2017.10.041_bib11","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib12","article-title":"Comprehensive characterization of 412 muscle-invasive urothelial carcinomas","volume":"35","author":"Lerner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.10.041_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.10.041_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2017.10.041_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.juro.2017.10.041_bib18","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2017.10.041_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2017.10.041_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2017.10.041_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","article-title":"Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma","volume":"1","author":"McDaniel","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.juro.2017.10.041_bib22","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib23","first-page":"783P","article-title":"Atezolizumab (atezo) in platinum (plat)-treated locally advanced\/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Ph II IMvigor210 study","volume":"27","author":"Loriot","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib24","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.10.041_bib26","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Bladder Cancer, version 5.2017","year":"2017"},{"key":"10.1016\/j.juro.2017.10.041_bib27","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib31","article-title":"Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)","volume":"35","author":"O'Donnell","year":"2017","journal-title":"Am Soc Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib32","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population","volume":"35","author":"Balar","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib33","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC)","volume":"35","author":"Hahn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib34","article-title":"Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy","volume":"35","author":"Perez-Gracia","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib35","unstructured":"Powles T, Loriot Y and Duran I: IMvigor 211: a phase III randomized study examining atezolizumab vs chemotherapy for platinum-treated advanced urothelial carcinoma. Presented at the 2nd Special Conference of European Association for Cancer Research-American Association for Cancer Research-Italian Cancer Society, Florence, Italy, June 24-28, 2017."},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib36","article-title":"Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: results from the phase II CheckMate 275 study","volume":"27","author":"Galsky","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib37","article-title":"Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN Solid Tumor study: updated analysis with \u22656 months of follow-up","volume":"28","author":"Apolo","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib38","article-title":"Planned survival analysis from KEYNOTE-045: phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC)","volume":"35","author":"Bajorin","year":"2017","journal-title":"Am Soc Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib39","article-title":"Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial","volume":"28","author":"De Wit","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and\u00a0activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.juro.2017.10.041_bib42","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib44","article-title":"Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial","volume":"35","author":"Patel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.juro.2017.10.041_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.juro.2017.10.041_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib48","article-title":"Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase II CheckMate 275 study","volume":"28","author":"Galsky","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.10.041_bib49","article-title":"Biologic and clinical relevance of an IFNG mRNA signature (IFNGS) and PD-L1 protein expression in tumor and immune cells in urothelial cancer (UC) patients (pts) treated with durvalumab (D)","volume":"35","author":"Bais","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.juro.2017.10.041_bib50","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"}],"updated-by":[{"DOI":"10.1016\/j.juro.2018.07.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000}}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717778160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717778160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.10.041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:05:42Z","timestamp":1651208742000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.10.041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1016\/j.juro.2017.10.041"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.10.041","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}